Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 11:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1633–1656 of 13,471 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Type 2 Diabetes Mellitus
Interventions: Efpeglenatide, Dulaglutide, Background therapy Metformin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 908 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 30
States / cities: Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 25 more

Conditions: Erectile Dysfunction, Hypogonadism, Male, Endothelial Dysfunction
Interventions: Daily low-dose PDE5 inhibitor therapy, Testosterone therapy as per clinical guidelines.; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older · Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Hyperparathyroidism
Interventions: Flurpiridaz PET/CT; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Ovary Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer
Interventions: Senaparib, Temozolomide; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Baltimore, Maryland • Philadelphia, Pennsylvania

Conditions: Diabetic Macular Edema (DME)
Interventions: UBX1325, Sham; Drug · Other
Lead sponsor: Unity Biotechnology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 19
States / cities: Phoenix, Arizona • Bakersfield, California • Encino, California + 15 more

Conditions: Chronic Kidney Disease, Diabetes, Obesity
Interventions: Social Cognitive Theory; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 40 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Pain Management, Cancer Pain
Interventions: Intrathecal Drug Delivery System, Conventional Medical Management; Device · Other
Lead sponsor: Flowonix Medical; Industry
Eligibility: 22 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Advanced Malignant Mesothelioma, Carcinoma of the Appendix, Ovarian Sarcoma, Ovarian Stromal Cancer, Pseudomyxoma Peritonei, Recurrent Colon Cancer, Recurrent Malignant Mesothelioma, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Stage III Colon Cancer, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage IV Colon Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: HIPEC Orientation, Consultation with Survivorship Navigator, Questionnaires; Behavioral · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Diabetes Mellitus Type 2
Interventions: GK Activator (2), Simvastatin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 2
States / cities: San Antonio, Texas • Tacoma, Washington

Conditions: Breast Cancer, Ovarian Cancer, Prostate Cancer, Colon Cancer, Renal Cancer
Interventions: Cyclophosphamide & ZYC300 (ZYC300 with cyclophosphamide pre-dosing); Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 2
States / cities: Boston, Massachusetts • Houston, Texas

Conditions: Epithelial Ovarian Cancer, Extraovarian Peritoneal Cancer, Fallopian Tube Carcinoma
Interventions: Ontak; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older · Female only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Infantile Refsum's Disease, Zellweger Syndrome, Adrenoleukodystrophy, Peroxisomal Disorders, Cholestasis
Interventions: Cholic Acids; Drug
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 2009
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Graves' Disease
Interventions: IMVT-1402, Placebo; Drug
Lead sponsor: Immunovant Sciences GmbH; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 33
States / cities: Tucson, Arizona • Concord, California • Aurora, Colorado + 28 more

Conditions: Colorectal Cancer Screening, Diabetes Mellitus, Type 2
Interventions: Targeted CRC Screening Toolkit; Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 50 Years to 74 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Diabetes Mellitus, Type 1
Interventions: Gan & Lee Insulin Lispro Injection, Humalog; Biological
Lead sponsor: Gan and Lee Pharmaceuticals, USA; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 58
States / cities: Anaheim, California • Fresno, California • Los Angeles, California + 52 more

Conditions: Pancreatic Ductal Adenocarcinoma, Stage I Pancreatic Cancer AJCC v8, Stage IA Pancreatic Cancer AJCC v8, Stage IB Pancreatic Cancer AJCC v8
Interventions: Activity Monitor, Quality-of-Life Assessment, Questionnaire Administration; Device · Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 50 Years to 75 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Omaha, Nebraska • New York, New York • Portland, Oregon

Conditions: Malignant Ovarian Clear Cell Tumor, Recurrent Ovarian Carcinoma
Interventions: Epacadostat, Pembrolizumab; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 351
States / cities: Anchorage, Alaska • Hot Springs, Arkansas • Little Rock, Arkansas + 209 more

Conditions: Diabetes, Prediabetes
Interventions: Clinical Decision Support; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 747 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Gestational Diabetes Mellitus, Pregnancy Complications
Interventions: Not listed
Lead sponsor: Long Island University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Mellitus, Type 1, Type 1 Diabetes Mellitus
Interventions: Diluted Humalog U-200 Insulin, Diluted U-500 Humulin Insulin, Lyumjev U-100 Insulin, Boost Mixed Meal Test; Drug · Dietary Supplement
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Diabetes Mellitus, Type 2
Interventions: Lixisenatide (AVE0010), Placebo, Basal Insulin, Metformin, Pen auto-injector; Drug · Device
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 496 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Diabetes, Heat, Perfusion; Complications
Interventions: Electrical stimulation; Device
Lead sponsor: Western Michigan University; Other
Eligibility: 45 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Type 2 Diabetes Mellitus
Interventions: Dapagliflozin, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 77 Years
Enrollment: 497 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 26
States / cities: Litchfield Park, Arizona • Phoenix, Arizona • Tempe, Arizona + 23 more

Conditions: Diabetes Mellitus, Type 2, Hypertension
Interventions: Canagliflozin, Placebo; Drug
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 54
States / cities: Birmingham, Alabama • Gulf Shores, Alabama • Avondale, Arizona + 51 more

Search by objective public record fields.

Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin

EndoPAT Device for Endothelial Dysfunction in ED

Flurpiridaz F-18 PET/CT Imaging for Detecting Parathyroid Adenomas

Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer

Safety, Tolerability and Evidence of Activity Study of UBX1325 in Patients With Diabetic Macular Edema (BEHOLD)

Diabetes CKD Lifestyle Technology Study

A Pilot Study to Evaluate the Efficacy of ITDD vs. CMM in the Treatment of Pancreatic Cancer Pain

Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

A Drug-Drug Interaction Study of GK Activator (2) and Simvastatin in Patients With Type 2 Diabetes.

A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing

A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer

Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

Aim 3, Optimizing CRC Screening in Patients With Diabetes in Safety-net Primary Care Settings

Gan & Lee Evaluation of New Biosimilar for Type 1 Lispro

Monitoring Heart Rate Variability for the Early Detection of Pancreatic Cancer

Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer

Reducing Type 2 Diabetes Diagnostic Delays Using Decision Support

Gestational Diabetes Mellitus (GDM) in Pregnant Women

Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin

Transcutaneous Electrical Stimulation and Controlled Heat in People With and Without Diabetes

Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes

Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents